Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Total Liabilities (2019 - 2025)

Historic Total Liabilities for Bolt Biotherapeutics (BOLT) over the last 7 years, with Q3 2025 value amounting to $33.0 million.

  • Bolt Biotherapeutics' Total Liabilities fell 1166.39% to $33.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.0 million, marking a year-over-year decrease of 1166.39%. This contributed to the annual value of $42.4 million for FY2024, which is 979.74% down from last year.
  • According to the latest figures from Q3 2025, Bolt Biotherapeutics' Total Liabilities is $33.0 million, which was down 1166.39% from $36.7 million recorded in Q2 2025.
  • In the past 5 years, Bolt Biotherapeutics' Total Liabilities ranged from a high of $58.6 million in Q3 2021 and a low of $21.4 million during Q1 2021
  • For the 5-year period, Bolt Biotherapeutics' Total Liabilities averaged around $45.6 million, with its median value being $47.1 million (2023).
  • In the last 5 years, Bolt Biotherapeutics' Total Liabilities crashed by 6055.51% in 2021 and then soared by 15433.17% in 2022.
  • Over the past 5 years, Bolt Biotherapeutics' Total Liabilities (Quarter) stood at $57.6 million in 2021, then decreased by 2.25% to $56.3 million in 2022, then fell by 16.44% to $47.0 million in 2023, then dropped by 9.8% to $42.4 million in 2024, then decreased by 22.35% to $33.0 million in 2025.
  • Its last three reported values are $33.0 million in Q3 2025, $36.7 million for Q2 2025, and $39.1 million during Q1 2025.